91ÖÆƬ³§ÔÚÏß¿´

CONCORDANCE OF A CAPILLARY BLOOD COLLECTION DEVICE FOR IMMUNE SURVEILLANCE IN PEDIATRIC SEPSIS; CRITICAL CARE MEDICINE; (2026).

DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia; Blood Advances; (2026).

Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling; JOURNAL OF BIOLOGICAL CHEMISTRY; (2026).

Azacitidine-panobinostat activates NF-kb signaling in the bone marrow microenvironment to chemosensitize KMT2A rearranged pediatric AML; BLOOD; (2025).

BTK regulates EZH2 stability in myeloid leukemia associated with down syndrome; BLOOD; (2025).

DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia; bioRxiv; (2025).

Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway; NATURE COMMUNICATIONS; (2025).

DYRKIA interacts with EZH2 to regulate transcriptionally active chromatin in myeloid leukemia associated with down syndrome; BLOOD; (2025).

Mechanism of acquired resistance to histone deacetylase inhibitor, romidepsin, in myeloid leukemia associated with down syndrome; BLOOD; (2025).

ST2/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche; NATURE COMMUNICATIONS; (2025).

Down syndrome and leukemia: An insight into the disease biology and current treatment options; BLOOD REVIEWS; (2024).

Identification of DLKI As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia; BLOOD; (2024).

Interferon Synergizes with Inhibition of Pro-Apoptotic Proteins to Reduce Leukemia Burden in PDX Models of ML-DS; BLOOD; (2024).

Mesothelin Promotes Acute Myeloid Leukemia Cell Proliferation, Adhesion, and Chemoresistance through Novel Partner; BLOOD; (2024).

Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine-Panobinostat Combination; CANCERS; (2023).

Tetraspanins set the stage for bone marrow microenvironment- induced chemoprotection in hematologic malignancies; BLOOD ADVANCES; (2023).

A Bone Marrow Mimetic 3D Co-Culture Model for Ex Vivo drug Testing of Down Syndrome-Myeloid Leukemia Cells; BLOOD; (2022).

An Insight into the Role of Mesothelin in Pediatric Acute Myeloid Leukemia; FASEB JOURNAL; (2022).

Azacitidine and Panobinostat Overcome Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A rearranged Pediatric AML; BLOOD; (2022).

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia; JOURNAL OF CLINICAL MEDICINE; (2022).

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts; JOURNAL OF CLINICAL MEDICINE; (2022).

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors; CANCERS; (2022).

Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21; CELLS; (2022).

Preclinical Validation of EZH2 and HDAC I Dual Inhibition As a Potent Therapy for Refractory Myeloid Leukemia Associated with Down Syndrome; BLOOD; (2022).

Selinexor Prolongs Survival in Patient-Derived Xenograft Models of Down Syndrome Myeloid Leukemia; BLOOD; (2022).

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML; BLOOD; (2022).

A 3-D hydrogel based system for hematopoietic differentiation and its use in modeling down syndrome associated transient myeloproliferative disorder; BIOMATERIALS SCIENCE; (2021).

Bcl2 Inhibitor and DNA Hypomethylating Agent Prolong Survival in Patient-Derived Xenograft Model of Down Syndrome Myeloid Leukemia By Synergistic Downregulation of Cytokine Signaling; BLOOD; (2021).

Epigenetic Drug Combination Alters Methylation Patterns in Patient-Derived Xenograft Models of KMT2A-Rearranged Pediatric AML Treated In Vivo; BLOOD; (2021).

Evaluating the Efficacy of PRMT5 Inhibitor C220 in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia; BLOOD; (2021).

Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies; CELLS; (2021).

Hydrogel-Based 3D Culture Model for Down Syndrome Associated Transient Myeloproliferative Disorder Using Customized Induced Pluripotent Stem Cells; BLOOD; (2021).

Imetelstat Significantly Reduces Leukemia Stem Cells in Patient-Derived Xenograft Models of Pediatric AML; BLOOD; (2021).

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies; CANCERS; (2021).

Introduction of STAG2 Mutation in an iPSC Model of Transient Abnormal Myelopoiesis Mimics Down Syndrome Myeloid Leukemia; BLOOD; (2021).

Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia; BLOOD ADVANCES; (2021).

T Cell Engaging Bispecific Antibodies Produce Durable Response in Mesothelin-Positive Patient-Derived Xenograft Models of Pediatric AML; BLOOD; (2021).

CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia.; Blood advances; (2020).

Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring.; BMC medical genomics; (2020).

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia; BLOOD; (2020).

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology.; Molecular therapy. Methods & clinical development; (2020).

Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples.; Genomics & informatics; (2020).

The extracellular matrix: A key player in the pathogenesis of hematologic malignancies.; Blood reviews; (2020).

Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer.; Frontiers in oncology; (2020).

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells; Blood; (2019).

Abstract LB-322: Identification of a novel fusion protein SPTAN1-ABL1 in a child with T-cell acute lymphoblastic leukemia: Functional characterization and therapeutic implications; Tumor Biology; (2019).

Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid Leukemia; Blood; (2019).

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML; Blood; (2019).

In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia; Blood; (2019).

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity; Blood; (2019).

Modeling Transient Myeloproliferative Disorder Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology; BLOOD; (2019).

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling; BLOOD; (2019).

Epigenetic Drug Combination Chemo-Sensitizes Pediatric AML By Reducing Cell Adhesion and Dislodging AML Cells from the Bone Marrow; BLOOD; (2018).

Epigenetic Drug Combination Overcomes Bone Marrow Microenvironment-Induced Chemoprotection in Pediatric Acute Lymphoblastic Leukemia Via Modulation of CD81; BLOOD; (2018).

Identification of novel fusion genes and expression variants in primary and patient-derived xenograft samples of pediatric leukemia using error-corrected RNA sequencing; CANCER RESEARCH; (2018).

Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.; Leukemia research; (2017).

Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.; Leukemia research; (2017).

Epigenetic drug treatment overcomes osteoblast-induced chemoprotection by suppressing cell adhesion and related signaling; CANCER RESEARCH; (2017).

Epigenetic modifiers outperform chemotherapy in prolonging survival in patient-derived xenograft models of Down syndrome AML; CANCER RESEARCH; (2017).

Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.; Seminars in oncology; (2017).

Knockdown of sodium-calcium exchanger 1 induces epithelial-to-mesenchymal transition in kidney epithelial cells.; The Journal of biological chemistry; (2017).

Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia; BLOOD; (2017).

Sodium-calcium exchanger-1 regulates the epithelial phenotype and is lost in renal cancers; CANCER RESEARCH; (2017).

Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice.; Frontiers in oncology; (2016).

Combination of epigenetic modifiers achieves complete remission in xenograft models of pediatric acute myeloid leukemia; CANCER RESEARCH; (2015).

Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy.; PloS one; (2015).

Distinct roles of Na, K-ATPase function and expression in medulloblastoma; CANCER RESEARCH; (2015).

Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,K-ATPase beta-1 subunit expression.; PloS one; (2015).

Ion dependence of Na-K-ATPase-mediated epithelial cell adhesion and migration.; American journal of physiology. Cell physiology; (2015).

Na,K-ATPase β1-subunit is a target of sonic hedgehog signaling and enhances medulloblastoma tumorigenicity.; Molecular cancer; (2015).

Sodium-calcium exchanger 1 regulates epithelial cell migration via calcium-dependent extracellular signal-regulated kinase signaling.; The Journal of biological chemistry; (2015).

Disruption of annexin II tetramer/receptor axis suppresses leukemia cell homing and engraftment; CANCER RESEARCH; (2014).

Inhibition of epidermal growth factor signaling by the cardiac glycoside ouabain in medulloblastoma.; Cancer medicine; (2014).

Metformin suppresses pediatric acute myeloid leukemia cell viability and clonogenicity; Cancer & Metabolism; (2014).

Regulation of Na,K-ATPase by Sonic hedgehog signaling in cerebellar granule precursor cells.; MOLECULAR BIOLOGY OF THE CELL; (2014).

Combination Of Inhibitors Against DNA Methyltransferases and Histone Deacetylases Synergistically Suppresses Cell Viability In Acute Myeloid Cells In a p53-Dependent Manner; BLOOD; (2013).

Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells.; Molecular cancer therapeutics; (2013).

Nanotechnology based drug delivery in childhood leukemia therapy: A novel approach to reduce side-effects.; CANCER RESEARCH; (2013).

Regulation of Na,K-ATPase β1-subunit in TGF-β2-mediated epithelial-to-mesenchymal transition in human retinal pigmented epithelial cells.; Experimental eye research; (2013).

Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine.; Molecular pharmaceutics; (2012).

Na,K-ATPase β-subunit cis homo-oligomerization is necessary for epithelial lumen formation in mammalian cells.; Journal of cell science; (2012).

Nanomedicine for the treatment of childhood leukemia; ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY; (2012).

Regulation of Na, K-ATPase β-subunit in TGF-β2-mediated epithelial-to-mesenchymal transition in human retinal pigmented epithelial cells.; MOLECULAR BIOLOGY OF THE CELL; (2012).

Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor.; Experimental cell research; (2011).

Dysfunction of ouabain-induced cardiac contractility in mice with heart-specific ablation of Na,K-ATPase beta1-subunit.; Journal of molecular and cellular cardiology; (2009).

Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin.; Cancer chemotherapy and pharmacology; (2009).

alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling.; Molecular cancer therapeutics; (2008).

Effects of Na,K-ATPase beta-subunit knockout on heart function; CIRCULATION; (2007).

Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.; International journal of oncology; (2007).

Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2; INTERNATIONAL JOURNAL OF ONCOLOGY; (2007).

Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.; International journal of oncology; (2007).

Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix; INTERNATIONAL JOURNAL OF ONCOLOGY; (2007).

Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature.; Microvascular research; (2006).

IDENTIFICATION OF PROTEIN KINASE C AS AN INTERMEDIATE IN NA, K-ATPASE BETA-SUBUNIT MEDIATED LAMELLIPODIA FORMATION AND SUPPRESSION OF CELL MOTILITY IN CARCINOMA CELLS; CELLULAR AND MOLECULAR BIOLOGY; (2006).

Identification of protein kinase C as an intermediate in Na,K-ATPase beta-subunit mediated lamellipodia formation and suppression of cell motility in carcinoma cells.; Cellular and molecular biology (Noisy-le-Grand, France); (2006).

Janus model of the Na,K-ATPase beta-subunit transmembrane domain: distinct faces mediate alpha/beta assembly and beta-beta homo-oligomerization.; Journal of molecular biology; (2006).

Na-K-ATPase regulates tight junction permeability through occludin phosphorylation in pancreatic epithelial cells.; American journal of physiology. Gastrointestinal and liver physiology; (2006).

Multiple functions of Na,K-ATPase in epithelial cells.; Seminars in nephrology; (2005).

HLA class I signal transduction is dependent on Rho GTPase and ROK.; Biochemical and biophysical research communications; (2004).

Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility.; Molecular biology of the cell; (2004).

The requirements for Ca2+, protein phosphorylation and concurrent protein synthesis for zeatin signaling of acidic chitinase transcript accumulation in Cucumis sativus L.; Journal of Plant Physiology; (2001).